antibody-drug conjugates

News

Adcendo licenses Multitude anti-TF ADC in $1bn+ deal

Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in variou

News

GSK bags breakthrough status for B7-H3 ADC for lung cancer

An antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion deal last year has been given breakthrough status by the FDA.

News

EU starts review of Enhertu in HER2-ultra-low breast cancer

The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) that could see the drug being used in advanced breast cancer with even lower levels of the HER

News

BiVictriX's chief executive Tiffany Thorn

Another AIM defection as BiVictriX plans to delist

The list of UK biotechs deciding to abandon listings on the AIM exchange in the UK just lengthened, after BiVictriX said it wants to cancel its shares and go private.

News

Myricx founders (l-r) Dr Andrew Bell, Dr Roberto Solari and Professor Ed Tate, with CEO Dr Robin Carr

Myricx raises £90m after pivot to ADCs for cancer

UK biotech Myricx Bio has tapped into the red-hot interest among investors for companies working on antibody-drug conjugates (ADCs) for cancer, raising £90 million ($115 million) in a first

News

FDA turns down MSD, Daiichi Sankyo HER3 ADC for lung cancer

The FDA has said it cannot approve MSD and Daiichi Sankyo’s HER3-targeted antibody-drug conjugate (ADC) patritumab deruxtecan because of problems at a third-party manufacturer.

Adcendo licenses Multitude anti-TF ADC in $1bn+ deal

GSK bags breakthrough status for B7-H3 ADC for lung cancer

EU starts review of Enhertu in HER2-ultra-low breast cancer

Another AIM defection as BiVictriX plans to delist

Myricx raises £90m after pivot to ADCs for cancer

FDA turns down MSD, Daiichi Sankyo HER3 ADC for lung cancer

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

antibody-drug conjugates

Editor's Picks